First, the widely used practice of bulk PBMC transduction with CAR constructs designed to treat HIV infection makes killer cells (CD4+) vulnerable to HIV-1 infection, which will certainly reduce the therapeutic effect. Here, CD4 is linked to HIV-1 infection.